Very exciting and surreal to be a part of this amazing cohort. @HHMINEWS #HannaGrayFellows. Thankful to @nytimes for promoting this amazing program. If you are eligible, please consider applying!

Our lab website is live! 🐟 vasilevalab.com We use genetic #zebrafish models and molecular oncology approaches to study pediatric cancer and discover new therapeutic strategies. We’re growing and recruiting postdocs and research technicians! #PediatricCancer #Zebrafish

My department at Oxford is recruiting junior faculty to the Ludwig Institute for Cancer Research. A collaborative and stimulating department, with great access to the breadth of the Oxford environment. The positions come with core funding and cutting edge technologies. If interested, apply here: shorturl.at/1ggGt

Scientific publishing needs to change. In a new preprint, HHMI President Erin O'Shea and Bodo Stern argue that the incentives are misaligned. Researchers should be evaluated on what they choose to share, not what journals select. I’m proud that @hhmi_science is leading the way. Read the preprint here: doi.org/10.5281/zenodo.19600…

The Chemical Biology of Anti-CRISPR Proteins (featuring the premiere of a brand-new CRISPR-inspired magic routine) Come see me become a doctor @ChemistryMIT Stay for the magic Or just show up for the free Insomnia Cookies April 15, 2026 | MIT 4-270 | 1:30 pm

What’s cooler than being cool? No dry ice. We’ve teamed up with Genovis to develop SEQguard™ Dino Preserve, a thermostable RNA protection solution for Plasmidsaurus RNA-Seq. Now you can ship purified RNA at room temp. No ice. No stress. Just fast, reliable RNA-seq. Read more plasmidsaurus.com/news/skip-…

I feel very privileged to start my group in the Center for Cancer and Immunology Research at @ChildrensNatl. Moving from California, I really appreciate this welcoming set - an umbrella and a scarf. 🌦️Passionate about science and pediatric cancer? We are recruiting!

Excited to share our latest study in 🩸Blood : IGH enhancer redirection to FOXF1 and KRAS mutations, define a novel high-risk B-ALL subtype! Huge 🙏to collaborators @EmmanuClappier, @IlariaIacobucc1, @CMullighan, and our team @UKSH_KI_HL.🔗doi.org/10.1182/blood.202503…

Now published in @MDPIOpenAccess Cancers: “Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma,” co‑authored by Drs. Houghton and Ignatius. 🔗 tinyurl.com/2z7huupy #PediatricCancer #Rhabdomyosarcoma #CancerResearch #NewPublication

@TempleHealth today announced the appointment of Robert A. Winn, MD, as the next Cancer Center Director for Fox Chase, marking a defining moment that will shape the future of one of the nation’s leading @theNCI designated Comprehensive Cancer Centers: bit.ly/47azyMA

JOIN US MONDAY! @VanderbiltCDB, @VUBasicSciences

Exciting seminar today @UWMadison by @willowcoyote redefining what rational drug design might look like!

Honored to be appointed the Alan A. and Edith L. Wolff Professor of Endocrinology at @washumedicine. Grateful to my colleagues, trainees, and collaborators helping us to advance stem cell-derived islet therapies toward transformative treatments for type 1 diabetes.

🧬 Studying how disease begins matters. Our next Gene Delivery Seminar is one week away. Sign up to learn how early genetic events underlying acute lymphoblastic leukemia are investigated in vivo.

What happens if you take a plant protein and transfer it into a human cell, and vice versa? We did this for 300 proteins that regulate epigenetics & found many surprises! A toolkit for programmable transcriptional engineering across eukaryotic kingdoms tinyurl.com/ymbndjd8

when reviewer 2 wants you to cite 3 texts by the same scholar

Is your funding for hematology research "Between a rock and a hard place" #fightforhematology funds from ASH members and fans now provide a new program: A R C H hematology.org/awards/career… NOTE: Are you doing well? .....your donations go 100% to lab support in the ARCH program.

Excited to share a recent publication from the lab. Daniel Benjamin & Jengmin Kang led the study of the allocation of resources to survival over reproduction in stem cells during aging. #EvolutionaryTradeOffs #SurvivorshipBias science.org/doi/10.1126/scie…

Please RT @hhmi_science #CechFellows Summer Undergraduate Research Experience - 9 weeks mentored research in an HHMI lab, $15K stipend, deadline to apply is 2 weeks away. See you next summer!

Today, we're announcing @episteme, a new type of R&D company that recruits exceptional scientists to pursue high-impact ideas. Science isn’t bottlenecked by the availability of talent, but by places where they can do their best work. Scientific progress has driven human flourishing: extending lifespans, lifting billions from poverty, and expanding our understanding of the universe. But history is littered with transformational ideas that were overlooked in their time. That problem is still acute today: too much promising talent remains uncultivated, and remarkable ideas die in the lab or are filtered out by misaligned incentives. Today, scientists face suboptimal paths for translating their research into impact: academia is famously risk-averse and incentivizes publications and winning grants vs. translational research. Industry is too often focused on short‑term incentives. And startups lack the substantial capital, expertise, and complex infrastructure needed to deliver long-term scientific progress. On top of that, recent funding cuts in the US mean the overall supply of ideas is decreasing. Put together, the global scientific production system is operating at a fraction of its capacity. How Episteme operates is different: we identify great scientists who can meaningfully benefit humanity, but who aren’t supported efficiently within traditional institutions today. Researcher by researcher, we work with them to determine the bespoke resources, operational support, and environmental conditions to execute on their research. We bring them together in-house, and provide those resources to ensure that their breakthroughs are deployed for real-world impact. We’ve already assembled an amazing team of operators, ranging from the Gates Foundation, DeepMind, ARPAs, DoE – just to name a few – and researchers who are pursuing important problems across physics, biology, computing, and energy. Our team has spoken to hundreds of researchers across disciplines and geographies to understand the limitations they’re facing and what can be done better, and designed Episteme for them. We’re backed by individuals like @sama, Masayoshi Son, and other long-term partners who share our mission of enabling ambitious science for tangible human impact. About me: I started working as a researcher 9 years ago, on problems ranging from AI-driven drug discovery to developing brain-machine interfaces. It was that experience that led me to realize that so many scientists with great potential to change the world don’t have access to opportunities equal to their capacities. @sama and I believe that much better science should happen for humanity, and that a new engine is needed to support that. We decided to cofound Episteme together, and I am incredibly grateful for Sam’s unwavering support as a thought partner and founding investor. Our conviction is that by supporting the right people with the right incentives, we're set to generate breakthrough discoveries to benefit humanity. We cannot rely on the course of history to shape scientific progress; we need to proactively shape the system by supporting the most talented people with the right resources and incentives.

Join Us! We are pleased to welcome Ava Carter, Ph.D., HHMI Hanna H. Gray Fellow, Harvard University on Tuesday November 11, 2025 at 3:00 PM in 1220 MRB III. Join us for an inspiring seminar highlighting her research in the lab of Michael E. Greenberg.